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nervous ystems in the occurrence of myocardial damage following aneurys- 
mal subarechnoid hemorrhage (SAH), we measured serum levels el MS-CK 
(MB), myosin light chain (Me) and trcponin T (Tn), and plasma concoctra- 
t~ons of coradranaline (NA), adrenaline (ADR) and MHPG as an indicator of 
NA activity of the brain in 720 SAH patients who admitted within 24 hours of 
the onset. Eighty patients had elevated levels of MB, Mn orTn that indicated 
myocardial damage (group A) and were compared to 640 patients without 
myocardial damage (group B). Myocardial damage in group A was related to 
the initial level of neurological severity, as assessed by WFNS grade, but was 
not related to the amount of subarachnoid blood visualized on the computed 
tomogram. There was no sigffdicant d~erence between two groups in b~oed 
pressure. Heart rate was significantly higher in group A than in group B (93 
29 vs 85 ± 20/mini p < 0.01). Plasma concentrations of NA, ADR and 
MHPG were significantly higher in group A than in group B (2316 + 4778 vs 
828 ~- 736 ~g/ml; p < 0.01,752 4-1129 vs 362 • 512 pg/ml; p < 0.01, and 23 
4- 26 vs 9 4- 6 ng/ml; p < 0.01, respectively), Inall patients, serum MB level 
had positive correlation with plasma NA, ADR and MHPG (r = 0.48, r = 0.50 
and r = 0.53, respectively), and Tn level also had positive correlation with 
plasma NA, ADR and MHPG (r = 0.75, r = 0.74 and r = 0,72, respect~valy). 
These results suggest hat noradrenergic activities in the central and pe- 
ripheral nervous ystems play an important role in the occurrence of myocar- 
dial damag~ ssociated with SAH. 
~ Three-Dimensional Measurements of Volume 
Plaques in the Arteria Carotis and the Arteria 
Femoralis 
C. Ebner, W. Tkalec, H.J, Nessec St. Elizabeth Hospital, Unz, Austria 
Non invasive plaque quantification and assesment of progression are main 
goals in ultrasound iagnostics. 
In 34 patients 114 ultrasound investigations were performed by three dif- 
ferent methods, using a 5 MHz linear array (Vingmed Masters ;~ade~). The 
probe was combined with a three dimensional (3D) reconsi,"uclion facility 
(TOMTEC). The documentation was realized by ECG- and breath-t~ggered 
6toting of the images in a transversal view. For optimal visualization an angle 
correction up 4- 30 degrees was possible. The plaque volume was cs:cu!~tsd 
based on sadal transversal sections by manual tracing of the plaque outlines. 
Each plaque was measured in one chosen mode by two experienced sono- 
graphers and once in another mode by the first sonographer. To validate the 
method we examined an in vitro plaque model. 
Results:We measured 39 subsignificant plaques (< 400 lumen reduction) 
in 29 carotid and 9 femoral arteries, A mean plaque volume of 77.5 cmm 
in examination I, 83.5 cmm in examination II, and 78.3 cmm in examination 
III was calculated. The interobservervadability ranged from 0.07 to 20.6 (m 
6.5)%, the intraobservervadability from 0.02 to 18.7 (m 8.1)%. The in vitro 
model with a defined volume of 1000 cmm was calculated between 931 
and 1106 (m 1044) cram with a mean interebservervadability of 6,3P/o. 
Additionally three dimensional reconstructions have been performed. 
In conclusion three dimensional plaque volume measurement isa promis- 
ing method for early detection of plaque progression in consecutive scans. 
Additional 3O reconstructions render a batter conception of the plaque ex- 
tention. 
~ Myocardial Involvement in Takayaau Arterltls 
K,K. Talwar, A.K. Goal, A. Saxena, D. Prabhakaran, P. Chopra, S. Sharma. 
Cardiothorac[c Sc[ances Center, All India Institute of Medical Sciences, New 
Delhi (INDIA) 
Congestive heart failure (CHF) is not an uncommon presentation i Takayasu 
artadtls (TA), To understand the pathogenesis of CHF in this disease we 
carded out endomyocerdial biopsy (EMB) in 85 patients (males 29, females 
56, age 2 to 42 yra) with angiographiceliy proven TA. The EMB was done 
form RV using cordis bioptome and 3 to 5 pieces were taken in 10% formalin 
for Nstologlcal examinatien. 
Myocardial involvement was present in 65 (76.~,%) and included fo- 
cal/dilfuse myocarditis in 26 (30,5%), myofiber hypertrophy in 39 (45.8('/o) 
and endocardlal thickening in 9 (10,6%). 39/65 (60%) with histological my- 
ocardial involvement had CHF. In 10 of these there was no associated 
hypettension or valvular involvement to account for CHF. Di6tdbution of my- 
ecardlal involvement did not show any predilection for the various types of TA 
as defined by Uano et al, Immunosupprossive therapy resulted in regression 
of myocerditis on repeat EMB and improvement ofCHF. 
Conclusion: Myocardial involvement appears to be common in TA and EMB 
should be done in all patients with CHF to detect undedying myocardifis. In 
view of its therapeutic importance itshould be incorporated in classification 
of TA. 
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~ Pulmonary Clearance of Circulating Endothelin-1 
in Dogs in Vivo: Exclusive Role of ETa Receptors 
Jocelyn Dupuis, Cad A, Gorssky, Alain Foumier. Montreal Heart Institute 
and INRS-Santd, Montreal, Canada 
The pulmonary circulation plays an important role in the removal of circulat- 
ing endothalin-1 (ET-1). Plasma ST-1 levals me increased in heart failure, 
purmcnary hypertension and congenital heart diseases and may partly result 
from reduced pulmonary clearance of this vasoactive peptide. We studied the 
rote of the ETA and ETa receptors fn the pulmonary clearance of [125]-I.ET-1 
in anesthetized ogs using the multiple indicator dilution technique. Experi- 
ments were carded out before and 5 minutes after intrapulmonary injection 
of specific antagonists for the ETA (BQ123) and ETa receptors (BQ788) 
(approximately 1 #mot per i~lion), 
Control BQ123 Control BQ788 
N=S N=6 
Flow (ml/s) 42 ± 10 42 ± 9 56 4- 26 51 ± 24 
HR (beats/rain) 160=1:20 169~:23 166±7 167±5 
MAP (mmHg) 149:1:23 143± 17 141 .;- 13 140:t: 13 
MPAP (mmHg) 14 ± 2.7 14 :i: 2 20 4- 2 20 + 3 
Ctaman~'e (%) 36 ~ 4.2 34 ~ 6A 33 ~: 7 0 ± 2* 
Kseq (s -~ ) 0.050 :k 0.009 0.047±0.014 0.052"+-0.019 - 
*p < 0.01 vs control; MAP = mean artadalpressure;MPAP = mean pulmonary artery pres. 
sure; Kseq = pulmonary sequestration rata constant for ET-1. 
ETA and ETs antagonists had no effect on systemic and pulmonary heine- 
dynamics. Pulmonary clearance was unaffected by BQ123 but was com- 
pletely abolished by SQ788 (from 33% to ~) ,  indicating that ST-1 is cleared 
exclusively by ETa receptors. 
Conclusions: The ETa receptor is exclusively responsible for pulmonary 
ST-1 clearance in vivo. Alterations or downregulation of this receptor may 
contribute to the increase in circulating ET-1 levels found in certain patho- 
logic conditions. These findings may also explain the observed rebound 
phenomenon after withdrawal of non-specific ETA and ETa antagonists. 
~ Captopril Reduces Endothelin,1 Release From 
Human Urnbllicel Vein Endothelial Cells by 
Reduction of Angiotensin II Synthesis 
Jan K~.hler, Stephan Baldt:s, Till v.Varendodf, Ralf K0ster, Wolfram Ten'as, 
Christien W. Hamm, Thomas Meinertz. Department of Cardiology, 
University Hospital Eppendoff, Hamburg, Germany 
Angiotensin converting enzyme (ACE) inhibitors reduce AT if synthesis and 
increase bradykinin (BK) levels. Angiotensin II (AT II) stimulates the synthesis 
of endothelin-1 (ET-1). Elevated SK levels augment he release of nitric oxide 
that is thought o be a major functional antagonist of ET-1 and decreases 
its synthesis. This study was conducted to determine whether the reduction 
of AT II induced by captopdl has an effect on the release of immunoreac- 
tive ET-1 (irET-1) from human umbilical vein endothelial cells. The effect of 
captcpdl on irET-1 release was compared to that of the AT1/AT2 receptor 
antagonists 106artan and CGP42112. Furthermore the effect of nitdc oxide on 
irET-1 release was investigated. Results: Captopfil reduced irET-1 release 
of cultured endothelial cells in a time and concentration dependent manner 
(60 + 8 fmof/10 s coils vs control 85 ± 6 fmol/10 s cells after 72 hou,~, p < 
0.05). The ATt/AT2 receptor antagonists Iosartan and CGP421t2 reduced 
irET-1 release in a concentration dependent and additive fashion (losartan 
46 ± 2Imol/10 s ceils, CGP42112 47 ~ 3 fmof/105 cells, Iosartan and COP 40 
± 3 tmolll0 s cells vs contre~ 50 ~ 4 fro01/10 s ceils, p < 0,05). The reduction 
of irET-1 release by captopril was not augmented by addition of Iosartan 
and CGP42112. The inhibition of nitdc oxide synthesis by NO-monomathyl 
L-arginine resulted in a minor increase in irET-1 levels. The increase of nitric 
oxide levels by 6ydnonimins had no influence on irET-1 release. Thus, it is 
concluded that ceptopdl reduces endothelin-1 release of cultured endothe- 
lial cells predominantly by decreasing angiotensin II synthesis but not by 
stimulation of the bradykinin/nitric oxide pathway, 
